Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Acquires Small San Diego Drug Discovery Firm Maxia Pharmaceuticals

NEW YORK, Nov. 12-Incyte Genomics plans to acquire Maxia Pharmaceuticals, a small San Diego-based drug discovery company, the firm said today.


Maxia, which has only 28 employees, is developing small molecule treatments for chronic diseases like diabetes, hyperlipidemia, and cancer, and has several lead compounds in preclinical development. Incyte is particularly interested in its success with small molecule inhibitors of protein phosphatases, said Incyte CEO Robert Stein in a statement.


Incyte will acquire the company for up to $28.3 million in cash and stock, plus up to $14 million in future milestone payments. Maxia will then become a subsidiary of Incyte. The boards of directors of both companies have approved the agreement, and it will be completed pending shareholder approval.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.